#USA #San Francisco #Hagens Berman #Inspire Medical #Inspire V

Inspire Medical's Troubling Launch and Legal Challenges

In the realm of medical technology, few events can shake investor confidence as much as a significant product launch that fails to deliver on its promises. Recently, Inspire Medical Systems, Inc. (NYSE: INSP) faced an unprecedented crisis as its stock plummeted by over 32%, primarily due to the problematic launch of its latest device, the Inspire V.

The Catalyst for the Downfall

The steep decline originated from the revelations surrounding the Inspire V's launch, which was plagued by operational readiness issues. According to national shareholder rights law firm Hagens Berman, which is spearheading legal action against Inspire Medical, the company misled investors about its preparedness for the device rollout. When management provided assurances of being 'ready to throw the switch,' they were allegedly hiding significant operational hurdles that hindered the launch's success.

Specifically, investors learned about critical failures in billing software that made it difficult for healthcare providers to process Medicare claims, slowing down the adoption of the new device. As a result, Inspire Medical had to slash its 2025 earnings per share (EPS) guidance by over 80%. This revelation not only devastated investor trust but also led to a staggering drop in the company's stock price, with shares falling by $42.04 each following the announcement.

Legal Investigation Unfolds

Partner Reed Kathrein of Hagens Berman commented on the legal perspective, stating, "Our investigation focuses on the discrepancies between the management's optimistic claims and the troubling realities they failed to disclose. We are zeroing in on the moment executives knew that essential updates for Medicare claims processing had not been implemented, effectively barring hospitals from billing adequately for procedures involving the Inspire V."

Other concerns raised include accusations that the company concealed an inventory surplus of the older Inspire IV devices, diminishing demand for the new Inspire V. This stifling effect on sales potentially misrepresented the company's position to investors.

The Deadline for Investors

Investors are being urged to act now, as the deadline to appoint a lead plaintiff in the securities class action lawsuit against Inspire Medical is January 5, 2026. This timeframe has intensified the urgency for those affected to consider their options. The lawsuit consolidates claims from investors who acquired Inspire Medical securities between August 6, 2024, and August 4, 2025, a period marked by significant misstatements regarding the company’s product cycle preparations.

Hagens Berman has a history of holding large corporations accountable, having secured over $325 billion in settlements for investors. Those who purchased Inspire shares during the relevant class period and suffered financial losses are encouraged to connect with the firm immediately to discuss their rights and potential recovery options.

A Call for Whistleblowers

The firm also invited whistleblowers with non-public information about Inspire Medical’s operations to consider contributing to the ongoing investigation, highlighting a possible avenue for securing rewards through the SEC Whistleblower Program. This program allows whistleblowers to earn compensation that can amount to 30% of any successful recovery made by the SEC stemming from their original information.

Conclusion

As the story unfolds with public interest growing, Inspire Medical faces not only a stock market crisis but also the considerable burden of legal scrutiny. Investors are left grappling with the fallout from the company's launch blunders and the looming discontent across their shareholder base. With events rapidly evolving, the coming days will be critical for both Inspire Medical and its stakeholders as they navigate the path ahead.